Next Article in Journal
Folate-Targeted mRNA Delivery Using Chitosan-Functionalized Selenium Nanoparticles: Potential in Cancer Immunotherapy
Next Article in Special Issue
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
Previous Article in Journal
Hydroxypyridinone-Diamine Hybrids as Potential Neuroprotective Agents in the PC12 Cell-Line Model of Alzheimer’s Disease
Previous Article in Special Issue
The Dark Side: Photosensitizer Prodrugs

Fighting Hypoxia to Improve PDT

Laboratoire Réactions et Génie des Procédés (LRGP), UMR 7274, CNRS, Université de Lorraine, 54000 Nancy, France
M.Kh. Dulaty Taraz State University, Taraz 080012, Kazakhstan
Laboratoire de Chimie Physique Macromoléculaire (LCPM), UMR 7375, CNRS, Université de Lorraine, 54000 Nancy, France
Biologie, Signaux et Systèmes en Cancérologie et Neurosciences, CRAN, UMR 7039, Université de Lorraine, CNRS, 54000 Nancy, France
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(4), 163;
Received: 30 September 2019 / Revised: 24 October 2019 / Accepted: 26 October 2019 / Published: 30 October 2019
(This article belongs to the Special Issue Photodynamic Therapy 2019)
Photodynamic therapy (PDT) has drawn great interest in recent years mainly due to its low side effects and few drug resistances. Nevertheless, one of the issues of PDT is the need for oxygen to induce a photodynamic effect. Tumours often have low oxygen concentrations, related to the abnormal structure of the microvessels leading to an ineffective blood distribution. Moreover, PDT consumes O2. In order to improve the oxygenation of tumour or decrease hypoxia, different strategies are developed and are described in this review: (1) The use of O2 vehicle; (2) the modification of the tumour microenvironment (TME); (3) combining other therapies with PDT; (4) hypoxia-independent PDT; (5) hypoxia-dependent PDT and (6) fractional PDT. View Full-Text
Keywords: PDT; oxygen; hypoxia PDT; oxygen; hypoxia
Show Figures

Figure 1

MDPI and ACS Style

Larue, L.; Myrzakhmetov, B.; Ben-Mihoub, A.; Moussaron, A.; Thomas, N.; Arnoux, P.; Baros, F.; Vanderesse, R.; Acherar, S.; Frochot, C. Fighting Hypoxia to Improve PDT. Pharmaceuticals 2019, 12, 163.

AMA Style

Larue L, Myrzakhmetov B, Ben-Mihoub A, Moussaron A, Thomas N, Arnoux P, Baros F, Vanderesse R, Acherar S, Frochot C. Fighting Hypoxia to Improve PDT. Pharmaceuticals. 2019; 12(4):163.

Chicago/Turabian Style

Larue, Ludivine, Bauyrzhan Myrzakhmetov, Amina Ben-Mihoub, Albert Moussaron, Noémie Thomas, Philippe Arnoux, Francis Baros, Régis Vanderesse, Samir Acherar, and Céline Frochot. 2019. "Fighting Hypoxia to Improve PDT" Pharmaceuticals 12, no. 4: 163.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop